Description

In this randomized controlled trial, a total of 240 patients divided evenly across the two participating IVF center will be recruited. Patients will be randomized to a control and to a treatment group, each containing 120 participants.

Only patients with at least one evaluable blastocyst will be randomized. Patients will undergo ovarian hyper-stimulation, oocyte retrieval, fertilization and embryo culture per standard clinical protocol determined by IVF center.

In the control arm, patients will undergo a single frozen embryo transferof the untested, best quality blastocyst. All other blastocysts with lower morphology will undergo trophectoderm biopsy on day 5, 6 or 7 and will be frozen. PGT-A results of the untransferred embryos will be revealed to the patient AFTER the outcome of the initial ET is known.

In the experimental arm, all embryos will be cultured to blastocyst and all viable blastocysts will undergo trophectoderm biopsy and PGT-A. PGT-A will be performed regardless of the number of blastocysts available. Patients will undergo frozen transfer of the single, best quality euploid blastocyst. If the initial transfer results in a non-conception cycle and additional embryos are available for transfer.

        Women undergoing IVF of between 35 and 40 years of age at IVF cycle start Utilization of
        Intracytoplasmic Sperm Injection ICSI (recommended) or Traditional IVF Utilization of
        ejaculated or testicular sperm Utilization of autologous or donor sperm All Controlled
        Ovarian Hyperstimulation (COH) protocols
        Exclusion Criteria:
        Utilization of donor oocytes Utilization of gestational carrier Recurrent Pregnancy Loss
        (RPL) defined as ≥ 3 consecutive miscarriages Recurrent Implantation Failure (RIF) defined
        as ≥ 3 more failed embryo transfers Preimplantation genetic testing for monogenic/single
        gene disorders (PGT-M) Translocation carriers